peptide hormone raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-06-19. Anything still debated is marked as such rather than presented as settled.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; visual inspection |
| Solubility | Soluble in water and aqueous buffers | Depends on pH, purity, and counterion |
| Typical storage | -20 °C or below, desiccated | Protect from light; avoid repeated freeze-thaw after reconstitution |
| Common analytical method | Reversed-phase HPLC and mass spectrometry | Purity by HPLC; identity and mass by LC-MS or MALDI-TOF |
| Common synonyms | hGH fragment 176–191; AOD-9604 | Names vary in research and product labeling |
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
=== Museums === Abbey House Museum, Leeds Armley Mills Industrial Museum, Leeds Bagshaw Museum, Batley Bankfield Museum, Halifax Bradford Industrial Museum, Eccleshill/Fagley, Bradford Brontë Parsonage Museum, Haworth Colne Valley Museum, Golcar, Huddersfield Eureka, Halifax Leeds City Museum, Leeds National Coal Mining Museum for England Overton, Wakefield National Media Museum, Bradford Pennine Farm Museum, Ripponden, Halifax Pontefract Museum Royal Armouries Museum, Leeds Thackray Museum, Leeds The Hepworth Wakefield Thwaite Mills, Leeds Tolson Museum, Dalton, Huddersfield Wakefield Museum, Wakefield West Yorkshire Folk Museum, Shibden Hall, Halifax Yorkshire Sculpture Park, West Bretton, Wakefield
MCln·xH2O + x SOCl2 → MCln + x SO2 + 2x HCl If an excess of SOCl2 is used to dehydrate aluminium trichloride, it will form an adduct (1 molecule of thionyl chloride for each molecule of the aluminium trichloride dimer).
By looking at Relaxation dispersion plots the data collect information on the thermodynamics and kinetics between the excited and ground. Saturation Transfer measures changes in signal from the ground state as excited states become perturbed. It uses weak radio frequency irradiation to saturate the excited state of a particular nuclei which transfers its saturation to the ground state. This signal is amplified by decreasing the magnetization (and the signal) of the ground state. The main limitations in NMR is that its resolution decreases with proteins that are larger than 25 kDa and is not as detailed as X-ray crystallography. Additionally, protein NMR analysis is quite difficult and can propose multiple solutions from the same NMR spectrum. In a study focused on the folding of an amyotrophic lateral sclerosis involved protein SOD1, excited intermediates were studied with relaxation dispersion and Saturation transfer. SOD1 had been previously tied to many disease causing mutants which were assumed to be involved in protein aggregation, however the mechanism was still unknown. By using Relaxation Dispersion and Saturation Transfer experiments many excited intermediate states were uncovered misfolding in the SOD1 mutants.
In the early 2000s, 7-Eleven and Dentsu introduced a corporate mascot named Open-Chan (Open 小將), an extraterrestrial dog who wears a rainbow-shaped crown from a fictional planet known as Planet Open to be a "cartoon spokesperson" for the store chain in Taiwan. Open-Chan quickly grew in popularity among Taiwanese children soon after its initial debut. After Open-Chan's subsequent rise to prominence in Taiwan, the character was even introduced in Japan. The unique convenience store culture formed by President Chain Store (7-Eleven in Taiwan) has become a part of Taiwanese culture. 7-Eleven Taiwan also operates an MVNO called ibon mobile, which offers prepaid and postpaid SIM cards using the FarEasTone network.
The superconducting transition temperature has been found to peak at an optimal doping value (p=0.16) and an optimal number of layers in each superconducting block, typically n=3. The undoped "parent" or "mother" compounds are Mott insulators with long-range antiferromagnetic order at sufficiently low temperatures. Single band models are generally considered to be enough to describe the electronic properties. Cuprate superconductors usually feature copper oxides in both the oxidation states 3+ and 2+. For example, YBa2Cu3O7 is described as Y3+(Ba2+)2(Cu3+)(Cu2+)2(O2−)7. The copper 2+ and 3+ ions tend to arrange themselves in a checkerboard pattern, a phenomenon known as charge ordering. All superconducting cuprates are layered materials having a complex structure described as a superlattice of superconducting CuO2 layers separated by spacer layers, where the misfit strain between different layers and dopants in the spacers induce a complex heterogeneity that in the superstripes scenario is intrinsic for high-temperature superconductivity.
Sources: en.wikipedia.org
=== Regulation of the insulin receptor signal === PI3K (phosphoinositide 3-kinase) is one of the important components in the regulation of the insulin signaling pathway. It maintains the insulin sensitivity in the liver. PI-3K is composed of a regulatory subunit (P85) and a catalytic subunit (P110). P85 regulates the activation of PI3K enzyme. In the PI-3K heterodimer (P85-P110), P85 is responsible for the PI3K activity, by binding to the binding site on the insulin receptor substrates (IRS). It was noted that an increase of P85 a (isoform of P85) results in a competition between the later and the P85-P110 complex to the IRS binding site, reducing the PI3K activity and leading to insulin resistance. Insulin resistance refers also to type 2 diabetes. It was also noted that increased serine phosphorylation of IRS is involved in the insulin resistance by reducing their ability to attract PI3K. The serine phosphorylation can also lead to degradation of IRS-1.
== Early life and education == Bibudhendra Sarkar was born on August 2, 1935, in Kushtia, Bengal, British India (now Bangladesh). His father, Surendra Nath Sarkar, was a lawyer, and his mother, Sucheta Sarkar (née Chaki), a homemaker, died when he was one year old. He completed his kindergarten and primary education at Kushtia Mission School, a Catholic institution. Following the Partition of India in 1947, Sarkar's family relocated to Calcutta after losing their possessions. He attended City College School and later City College, Kolkata, earning his Matriculation and Intermediate Science certifications from the University of Calcutta. He pursued higher education at Banaras Hindu University in Uttar Pradesh, specializing in the chemistry of natural products and earning Bachelor of Pharmacy (B.Pharm) and Master of Pharmacy (M.Pharm) degrees. During his undergraduate studies, Sarkar worked as a summer researcher at the Central Drug Research Institute in Lucknow, under the mentorship of Manojit Mohan Dhar, who encouraged him to pursue graduate studies abroad. He subsequently moved to the United States, completing a PhD in biochemistry at the University of Southern California in 1964 under the supervision of Paul Saltman. At USC, his work was influenced by chemists Sydney Benson (chemical kinetics), Arthur Adamson (physical chemistry), and Bo Malmström (metal-activated enzyme chemistry).
An association between osteoporosis, another disease characterized by the degradation of bony tissue, and sarcopenia, the age-related degeneration of muscle mass and quality have also been found. Whether this link is a result of direct regulation or a secondary effect through muscle mass is not known. A link in mice between the concentration of myostatin in the prenatal environment and the strength of offspring's bones, partially counteracting the effects of osteogenesis imperfecta (brittle bone disease) has been found. Osteogenesis imperfecta is due to a mutation that causes the production of abnormal Type I collagen. Mice with defective myostatin were created by replacing sequences coding for the C-terminal region of myostatin with a neomycin cassette, rendering the protein nonfunctional. By crossbreeding mice with the abnormal Type I collagen and those with the knockout myostatin, the offspring had "a 15% increase in torsional ultimate strength, a 29% increase in tensile strength, and a 24% increase in energy to failure" of their femurs as compared to the other mice with osteogenesis imperfecta, showing the positive effects of decreased myostatin on bone strength and formation.
This is a list of scandals or controversies whose names include a -gate suffix, by analogy with the Watergate scandal in the 1970s, as well as other incidents to which the suffix has (often facetiously) been applied. This list also includes controversies that are widely referred to with a -gate suffix, but may be referred to by another more common name (such as the New Orleans Saints bounty scandal, known as "Bountygate"). Use of the -gate suffix has spread beyond American English to many other countries and languages.
Sources: en.wikipedia.org
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.
Mass spectrometry, such as LC-MS or MALDI-TOF, confirms the molecular mass and can reveal sequence-related impurities. Reversed-phase HPLC is used for purity, and peptide mapping or amino acid analysis can support sequence identity. No single method establishes every quality attribute.
No. AOD9604 is a short synthetic fragment of the hGH sequence, not the full 191-amino-acid hormone. It lacks the regions that mediate hGH receptor activation and growth-promoting effects. Products labeled as AOD9604 should not be assumed to have the same properties as hGH.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.